Opendata, web and dolomites

GO-DS21 SIGNED

Gene overdosage and comorbidities during the early lifetime in Down Syndrome

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "GO-DS21" data sheet

The following table provides information about the project.

Coordinator
CENTRE EUROPEEN DE RECHERCHE EN BIOLOGIE ET MEDECINE 

Organization address
address: Rue Laurent Fries 1
city: ILLKIRCH GRAFFENSTADEN
postcode: 67404
website: www.igbmc.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 5˙965˙967 €
 EC max contribution 5˙965˙967 € (100%)
 Programme 1. H2020-EU.3.1.1. (Understanding health, wellbeing and disease)
 Code Call H2020-SC1-2019-Two-Stage-RTD
 Funding Scheme RIA
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2024-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CENTRE EUROPEEN DE RECHERCHE EN BIOLOGIE ET MEDECINE FR (ILLKIRCH GRAFFENSTADEN) coordinator 1˙029˙185.00
2    HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH DE (NEUHERBERG) participant 928˙025.00
3    QUEEN MARY UNIVERSITY OF LONDON UK (LONDON) participant 579˙885.00
4    KING'S COLLEGE LONDON UK (LONDON) participant 567˙998.00
5    FUNDACIO CENTRE DE REGULACIO GENOMICA ES (BARCELONA) participant 554˙556.00
6    INSTITUT DU CERVEAU ET DE LA MOELLE EPINIERE FR (PARIS) participant 540˙000.00
7    THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE UK (CAMBRIDGE) participant 440˙530.00
8    FUNDACIO INSTITUT MAR D INVESTIGACIONS MEDIQUES IMIM ES (BARCELONA) participant 391˙744.00
9    Concentris Research Management GmbH DE (Fürstenfeldbruck) participant 370˙000.00
10    INSTITUT JEROME LEJEUNE FR (PARIS) participant 344˙043.00
11    PERHA PHARMACEUTICALS SAS FR (ROSCOFF) participant 200˙000.00
12    TRISOMY 21 RESEARCH SOCIETY NL (GRONINGEN) participant 20˙000.00

Map

 Project objective

The aim of the project is to elucidate etiological mechanisms involved in the appearance of obesity, and intellectual disability comorbidities in Down syndrome (DS). With its incidence of 1 in 1000 births, DS offers a great opportunity to uncover common/novel mechanisms because it is associated with a higher risk to develop several obesity, and intellectual disability. The increased risk to develop this combination of comorbidities in DS, suggests that specific genetic or epigenetic mechanisms associated with trisomy 21 (the cause of DS) predispose to this comorbidity. For this aim, GO-DS21 will have the following objectives: 1) To determine age-related comorbidity patterns observed over the early lifetime (before age 45) in persons with Down syndrome (WP1). 2) To identify specific physiological biomarkers (WP4), and regulatory and epigenetic signatures (WP5) in human, cellular and animal models. 3) To decipher the contribution of environmental factors (stress, diet, exercise) to trisomy 21 obesity/ID comorbidities in preclinical models (WP2, 3). 4) To investigate the effects of overdosage of three Hsa21 candidate genes (DYRK1A, MRAP, NRIP1) to explain comorbid patterns in mouse models (WP3). 5) To integrate multilevel data from human patients, preclinical and cellular models across different spatial and temporal scales of biological complexity using computational biology models and machine learning approaches (WP6). 6) To design new therapeutic interventions to reduce the penetrance of comorbidities in preclinical models (WP3 and WP4). This approach will help to improve diagnosis and understanding of prognostic factors, and will establish recommendations and targeted interventions to prevent or minimise comorbidities in persons with DS (WP7). Beyond the impact for patients with DS we expect that findings of this project will also be beneficial for patients in the general population.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GO-DS21" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GO-DS21" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.1.)

BIND (2020)

Brain Involvement iN Dystrophinopathies

Read More  

DECISION (2020)

DECOMPENSATED CIRRHOSIS: IDENTIFICATION OF NEW COMBINATORIAL THERAPIES BASED ON SYSTEMS APPROACHES

Read More  

DC-ren (2020)

Drug combinations for rewriting trajectories of renal pathologies in type II diabetes (DC-ren)

Read More